Final answer:
Glyburide stimulates the production and release of insulin from the pancreas and may not be appropriate to take if morning glucose levels are low; additionally, its use should be paused after receiving IV contrast media to avoid potential risks such as hypoglycemia.
Step-by-step explanation:
When teaching a patient with type 2 diabetes about glyburide, a nurse should include that glyburide stimulates insulin production and release from the pancreas. This medication is part of the sulfonylurea class of drugs which acts on the pancreatic beta cells enhancing their function. It is crucial to monitor blood glucose levels while taking glyburide because it can cause hypoglycemia if blood glucose is too low. Therefore, it may not be advisable to take glyburide if the morning blood glucose level is low without first consulting a healthcare provider.
Additionally, the use of glyburide should be paused (typically for about 48 hours) after receiving intravenous (IV) contrast media because of the potential risk of acute kidney injury which can alter drug function and elevate the risk of hypoglycemia.
Glyburide does not decrease glucagon secretion. Instead, glucagon is released by the pancreas in response to low blood glucose levels and works by raising blood glucose, an effect opposite to that of insulin and sulfonylureas like glyburide.